Endo International plc – Ordinary Shares (NASDAQ:ENDP) reported third quarter 2016 financial results, including:
- Revenues of $884 million including the addition of sales from its 2015 acquisition of Par Pharmaceutical, a 19 percent increase compared to third quarter 2015 revenues of $746 million.
- Reported net loss from continuing operations of $191 million compared to third quarter 2015 reported net loss from continuing operations of $804 million.
- Reported diluted loss per share from continuing operations of $0.86 compared to third quarter 2015 reported diluted loss per share from continuing operations of $3.84.
- Adjusted net income from continuing operations of $226 million, a 5 percent increase compared to third quarter 2015 adjusted net income from continuing operations of $214 million.1
- Adjusted diluted EPS from continuing operations of $1.01 compared to third quarter 2015 adjusted diluted EPS from continuing operations of $1.02.1
“During the third quarter 2016, Endo further sharpened its focus on operational execution. We have continued to deliver results across all of our businesses that are on-track or ahead of Company expectations for the quarter. Today we are reaffirming our full year 2016 revenue and adjusted diluted EPS financial guidance,” said Paul Campanelli, President and CEO of Endo. “This is an important time for Endo. The leadership team is working closely and collaboratively to build on our strengths and develop a go-forward strategy that best positions the Company to improve the lives of the patients and customers we serve.” (Original Source)
Shares of Endo are currently falling nearly 6% to $14.70 in pre-market trading. ENDP has a 1-year high of $63.71 and a 1-year low of $12.56. The stock’s 50-day moving average is $20.67 and its 200-day moving average is $19.37.
On the ratings front, ENDP stock has been the subject of a number of recent research reports. In a report issued on November 2, Mizuho analyst Irina Rivkind Koffler reiterated a Buy rating on ENDP, with a price target of $29, which represents a potential upside of 85% from where the stock is currently trading. Separately, on October 14, Guggenheim’s Louise Chen reiterated a Buy rating on the stock and has a price target of $35.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Irina Rivkind Koffler and Louise Chen have a yearly average return of 14.9% and a loss of 17.4% respectively. Koffler has a success rate of 45% and is ranked #95 out of 4181 analysts, while Chen has a success rate of 26% and is ranked #4015.
The street is mostly Neutral on ENDP stock. Out of 9 analysts who cover the stock, 5 suggest a Hold rating and 4 recommend to Buy the stock. The 12-month average price target assigned to the stock is $26.00, which represents a potential upside of 66% from where the stock is currently trading.
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. It operates through the following segments U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The Devices segment offers medical devices that deliver innovative medical technology solutions to physicians treating female incontinence and pelvic floor repair. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets.